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Amplification of MYCN in neuroblastoma strongly correlates to unfavorable outcome, but little is known of how
the high MYCN expression translates into an aggressive tumor phenotype. More aggressive neuroblastomas
are generally immature and overexpression of exogenous MYCN in cultured neuroblastoma cells and other
neuronal cell types has been reported to inhibit induced differentiation, suggesting a link between high MYCN
expression and an immature phenotype. However, we show here that MYCN is expressed in human neuroblasts
of sympathetic chain ganglia at fetal week 8.5, a developmental stage at which these neuroblasts express a
number of sympathetic neuronal differentiation marker genes. Analyses of 28 neuroblastoma tumor specimens
and 27 cell lines for the expression of MYCN and a panel of neuronal differentiation marker genes did not reveal
any correlation between MYCN and marker gene expression levels. Finally, we tested five separate
differentiation protocols and show that MYCN overexpressing neuroblastoma cells with a neuronal phenotype,
derived from the non-MYCN-amplified human neuroblastoma cell line SK-N-SH, retain their capacity to
differentiate despite constitutive MYCN overexpression. Our results show that high MYCN expression and
sympathetic differentiation are compatible, and indirectly our findings lend support to previously published
MYCN neuroblastoma tumor data, which suggest that in single MYCN copy neuroblastomas there is no direct
correlation between a high cellular MYCN protein content and aggressive tumor cell behavior.
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The MYC family consists of three closely related
transcription factors encoding the proto-oncogenes
MYC, MYCN, and MYCL (also known as MYCC or c-
myc, N-myc, and L-myc, respectively). MYC is the
founding member, whose transforming properties
were first evidenced by the pioneering studies on
avian retroviruses. Subsequently, increased expres-
sion of MYC oncogenes due to translocations or
genomic amplification was detected in various
human neoplasms. Over the past 15 years, evidence
has accumulated supporting a role for MYC in a
variety of cellular pathways controlling cell growth,
differentiation, cell adhesion, angiogenesis, apopto-
sis, immortalization, and genome stability.
Amplification of MYCN occurs in a number of
childhood and adult tumors and is a hallmark of a
genetic subgroup (22% of all cases1–7) of highly
aggressive neuroblastomas, that is, pediatric sympa-
thetic nervous system-derived tumors. Early on,
MYCN amplification was recognized as an indepen-
dent prognostic factor for neuroblastoma and was
used as one of the first genetic markers in therapy
stratification for cancer treatment. In parallel to
observations for MYC, increased MYCN expression
was thought to be essential for constituting the
malignant phenotype. Consistent with this assump-
tion, overexpression of MYCN, targeted to sympa-
thetic precursor cells via the tyrosine hydroxylase
promoter in transgenic mice, results in the develop-
ment of tumors with neuroblastoma characteristics.8
Recent evidence for a role in perturbed growth
control came from the finding that postmitotic
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sympathetic neurons could be induced by MYCN to
re-enter the S phase of the cell cycle.9 Furthermore,
overexpression of MYCN in the epithelial neuro-
blastoma subclone SH-EP resulted in increased DNA
synthesis and growth rate.10 An extended expression
analysis of these cells, in which the MYCN gene is
under a controllable promoter, revealed that the
majority of MYCN-induced genes are regulators of
protein synthesis, and many of these genes were also
induced by MYC in melanoma cells.11
Insights into the role of MYCN in differentiation
and tumor development might indirectly be de-
duced from our current knowledge of MYC,
although evidence indicates separate roles for the
MYC family members. The identification and, in
particular, the validation of MYC and MYCN target
genes and the dissection of the cellular network
governed by both genes, has, however, proven
extremely difficult and our understanding of the
exact role of MYC or MYCN in the abovementioned
pathways is, as yet, poor. In normal avian and
murine development, MYCN is expressed preferen-
tially during early embryogenesis with high expres-
sion at the time of organogenesis.12,13 In general,
major sites of MYCN expression correlate to regions
of differentiating cells, rather than to areas with high
proliferation rates.13–15 Of particular relevance for
the present study is the high MYCN expression in
neural crest-derived progenitor cells. In avian cells,
a role for MYCN in controlling cell migration and
neuronal determination or early differentiation of
neural crest-derived cells is suggested.16 In mice,
homozygous elimination of MYCN is lethal and the
sympathetic nervous system (SNS) has fewer neuro-
blasts, but those that remained appeared to develop
normally.17 These observations from developmental
studies are, however, contrasted by reports of
blocked retinoic acid (RA)-induced differentiation
and growth arrest by exogenous MYCN overexpres-
sion in neuroblastoma cell lines carrying an ampli-
fied MYCN gene.18,19
As MYCN amplification is closely associated to
high-stage neuroblastomas and an inverse correla-
tion between clinical neuroblastoma stage and the
expression of differentiation marker genes has been
established,20 a role for MYCN in differentiation
arrest can be inferred. However, although MYCN-
amplified neuroblastoma tumors consistently show
increased MYCN expression both at the mRNA and
the protein level,21–23 a closer examination reveals
that MYCN single-copy low-stage neuroblastoma
tumors (stages 1, 2, and 4S) also can express high
MYCN levels, seemingly without affecting either the
malignant status of the tumor or patient outcome. In
contrast, some, but not all, reports on non-MYCN-
amplified tumors at higher clinical stages conclude
that high MYCN expression correlates to poor
outcome.24–26
In this report, we have addressed the putative role
of MYCN in blocking neuronal differentiation of
human neuroblastoma cells. We have analyzed the
expression levels of MYCN and correlated them to
the expression of established sympathetic neuronal/
neuroendocrine marker genes in a panel of neuro-
blastoma cell lines and tumor specimens. We have
further used MYCN-transfected clones of SK-N-SH
neuroblastoma cells,27 which are non-MYCN ampli-
fied and have the rare capacity to differentiate
neuronally by several different protocols, to study
the effect of overexpression of MYCN on induced
differentiation. Taken together, our tumor and cell
line data strongly suggest that the overall capacity of
neuroblastoma cells to undergo neuronal differen-
tiation is not impaired by high MYCN expression.
Materials and methods
Tumor Material, Cell Lines, and Cell Culture
Conditions
The clinical material consisted of 13 stage 1, 2, and
4S tumors and 15 stage 3 and 4 tumors. Seven of
them had an amplified MYCN gene. SK-N-SH, SH-
SY5Y, KCN-69n, and SK-N-BE (2) cells were
cultured in Eagle’s minimum essential medium with
10% fetal calf serum, 100 IU/ml penicillin V, and
100 mg/ml streptomycin added. SH-EP cells were
supplied with the same medium and antibiotics, but
with 15% fetal calf serum. All other neuroblastoma
cell lines were cultured in RPMI 1640 with 10%
fetal calf serum and antibiotics as above. The
SKMYC2 clone of SK-N-SH cells transfected with
human MYCN has previously been described.27
Briefly, MYCN cDNA (from pcNMYC3, Dr JM
Bishop, University of California, San Francisco,
CA, USA) was cloned into an RSV-LTR-driven
expression vector in either sense or antisense
orientation. Stable transfectants were achieved
using calcium-phosphate precipitation and selec-
tion for expression of the hygromycin resistance
gene also on the pREPcNMYC2 (sense) and pRE-
PcNMYCAS2 (antisense) plasmids. The cells were
then cultured as SK-N-SH cells with 200–600 mg/ml
Hygromycin B (Calbiochem, San Diego, CA, USA)
added. To induce differentiation, the following
additives were used: All-trans-retinoic acid (RA)
(Sigma, St Louis, MO, USA), aphidicolin (Sigma),
12-O-tetradecanoyl-phorbol-13-acetate (TPA) (Sig-
ma), basic fibroblast growth factor (bFGF), brain-
derived neurotrophic factor (BDNF), insulin-like
growth factor-I (IGF-I), and nerve growth factor
(NGF), all growth factors from PeproTech EC Ltd,
London, England. Media and antibiotics were
purchased from Life Technologies Inc (Rockville,
MD, USA), and fetal calf serum from PAA Labora-
tories GmbH, Linz, Austria.
Immunohistochemistry and In situ Hybridization
Human fetal tissue (ethical approval LU 389-98,
Lund University, Sweden) was obtained from
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elective abortions and the material was fixed in
formaldehyde and paraffin embedded. Abdominal
cross-sections (5 mm thick) were secured onto glass
slides and deparaffinized. Immunohistochemistry
was performed as described,28 using avidin–biotin–
peroxidase conjugated secondary antibodies (ABC-
kit, Vectastain, Vector Laboratories, Burlingame, CA,
USA) and diaminobenzidine as chromogen. The
primary antityrosine hydroxylase (TH) monoclonal
antibody (Roche Molecular Biochemicals, Man-
nheim, Germany) was used at a 1:75 dilution. Slides
were counterstained with hematoxylin. For in situ
hybridizations, sections were pretreated as de-
scribed.29 MYCN RNA transcripts were detected
with an antisense-oligonucleotide mouse sequence
probe, with hybridization conditions essentially as
described.30 The following oligonucleotides were
used: Antisense probe: 50-AAG TAG AAG TCA TCT
TCG TCC GGG TAG AAG CAG GGC TGC A-30, sense
probe: 50-CGA TTT CCT CCT CTT CAT CTT CCT
CCT CGT CAT CCT CAT C-30 (Invitrogen AB,
Stockholm, Sweden, custom-made primers). The
oligonucleotides were 30-endlabeled with 35S-dATP
using terminal deoxyribonucleotidyl transferase.
The sections were hybridized at 421C overnight
and washed four times in 1SSC at 561C. The sense
probe was used as hybridization control.
Immunofluorescence and Western Blot Analyses
Cells intended for immunofluorescence were plated
on glass coverslips, treated as described in the
Results section, fixed with 4% paraformaldehyde in
PBS, and mounted on object slides with 20ml PVA-
DABCO solution (9.6% polyvinyl alcohol, 24%
glycerol, and 2.5% 1,4-diazabicyclooctane in
67 mM Tris-HCl, pH 8.0). TBS with 5% goat serum
and 0.3% Triton X-100 was used as blocking and
permeabilization buffer, anti-MYCN antibody
(556438 from BD Pharmingen, San Diego, CA,
USA) diluted 1:100 in blocking and permeabiliza-
tion buffer as primary, and goat anti-mouse IgG-
FITC-conjugated antibodies (Alexa Fluor 488, Mole-
cular Probes, Inc., Eugene, OR, USA) diluted 1:100
in TBS as secondary antibodies. The results were
documented with or without FITC-filters, using a
SONY DKC 5000 camera system (Sony Corporation,
Tokyo, Japan). For Western blot analysis, cells were
lysed in 10 mM Tris-HCl (pH 7.2), 160 mM NaCl, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% SDS,
1 mM EGTA, 1 mM EDTA in the presence of
complete protease inhibitor (Roche). A measure of
40–60 mg of whole-cell lysate proteins were sepa-
rated on an SDS-PAGE gel and blotted onto an
Immobilon-P membrane (Millipore Corporation,
Bedford, MA, USA). The following primary anti-
bodies were used: anti-actin antibody (ICN Biome-
dicals Inc., Costa Mesa, CA, USA), diluted 1:2500
and anti-MYCN antibody (556438 from BD Pharmin-
gen) diluted 1:500. HRP-coupled secondary anti-
body fragments were supplied from Bio-Rad
Laboratories, Hercules, CA, USA (diluted 1:3000)
or Amersham Pharmacia Biotech, Uppsala, Sweden
(diluted 1:5000). Rainbow RPN 756 (Amersham) was
used as a molecular weight marker.
Northern Blot and Quantitative RT-PCR Analyses
A commercial guanidine–isothiocyanate/phenol–
chloroform extraction solution (Trizol, Invitrogen
Inc., Carlsbad, CA, USA) was used for isolation of
total cellular RNA. For Northern blot analysis, 15 mg
of RNA was electrophoretically separated on a 1%
agarose–formaldehyde gel and blotted onto a nylon
membrane (Hybond-N, Amersham). The following
cDNA probes were labeled with [32P]dCTP using an
oligonucleotide labeling kit (Amersham Pharmacia
Biotech): GAP43,31 GAPD,32 HES1,33 NPY,34 and
MYCN.2 Hybridizing probes were visualized by
autoradiography (Curix Blue HC-S Plus, Agfa-Ge-
vaert N.V. Mortsel, Belgium). DNase treatment,
cDNA synthesis, primer design, and SYBR Green I
real-time quantitative RT-PCR were performed as
described35 with minor modifications. After estab-
lishment of amplification efficiencies 495% for all
primer pairs, the comparative Ct method was used
for quantification. PCR reagents were obtained from
Eurogentec as SYBR Green I mastermixes and used
according to the manufacturer’s instructions in a
total volume of 25ml. Reactions were run on an
ABI5700 (Applied Biosystems) in duplex (coeffi-
cient of variation for calculated quantities always
below 10%). Gene expression levels were normal-
ized using the geometric mean of the four most
stable internal control genes in neuroblastoma (ie
UBC, HPRT1, SDHA, and GAPD) as reported
previously.36 Primer sequences for all tested genes
are available in the public RTPrimerDB database
(http://www.realtimeprimerdatabase.ht.st) (gene
(RTPrimerDB-ID): UBC (8), SDHA (7), HPRT1 (5),
GAPD (3), MYCN (180), MYC (18), HAND2 (98),
NTRK1 (118), GAP43 (97), STMN2 (129), CHGA
(474), INHBA (105)).37
Results
MYCN is Expressed in Developing Human
Sympathetic Neuroblasts
To verify that MYCN is expressed during develop-
ment of the human SNS, MYCN expression was
analyzed in abdominal cross-sections of an 8.5-
week-old human fetus. At this developmental stage,
sympathetic chain ganglia are under formation and
TH-positive sympathetic precursor cells are popu-
lating the developing adrenal glands (Figure 1c). As
shown in Figure 1a and b, strong MYCN expression
was detected in dorsal root ganglia, sympathetic
chain ganglia, and in the spinal cord. Interestingly,
the migrating sympathetic adrenal precursor cells
MYCN and neuroblastoma differentiation
A Edsjo¨ et al
3
Laboratory Investigation (2004) 1–12
appeared not to express MYCN, or are at the most
expressing MYCN modestly (compare TH-positive
cells in panel c with the in situ signal in the
corresponding areas in panels a and b). we conclude
that human sympathetic chain ganglion neuroblasts
express MYCN at a stage when these cells are
nonmigrating and when they express a number of
sympathetic neuronal marker genes.38–40
Expression of MYCN and Neuronal Marker Genes in
Neuroblastoma Cells and Tumors
The stage of differentiation based on morphological
criteria has for a long time been used as a prognostic
factor in neuroblastoma, and in line with this,
expression levels of differentiation markers such as
neuron-specific enolase, synaptophysin, and the
neuronal form of pp60c-src correlate positively to
favorable outcome.20,41.MYCN amplification is asso-
ciated with an aggressive phenotype and when
MYCN is overexpressed in MYCN-amplified cul-
tured neuroblastoma cells, RA differentiation is
blocked.18,19 However, as the link between MYCN
expression and prognosis or tumor stage in non-
MYCN-amplified neuroblastomas is contradic-
tory,25,42 we analyzed a panel of neuroblastoma cell
lines and tumor specimens for the expression of
MYCN and a set of SNS differentiation markers by
quantitative real-time RT-PCR (Figure 2). In the 27
analyzed cell lines, the highest MYCN expression
was found in those derived from MYCN-amplified
tumors. Similarly, in the panel of 28 investigated
tumor specimens, MYCN expression was, with one
exception, highest in tumors with an amplified gene
(Figure 2). The five analyzed SNS neuronal/neuro-
endocrine differentiation marker genes, HAND2
(dHAND), NTRK1 (trkA), GAP43, STMN2 (SCG-10),
and CHGA (chromogranin A), were with few
exceptions expressed in all cell lines, which first
of all confirms the SNS and neuroblastoma deriva-
tion of the analyzed tumor cell lines. However, there
was no correlation between MYCN expression and
the expression levels of the differentiation markers
(Table 1),44 which can be demonstrated visually by
ordering the cell lines according to MYCN expres-
sion levels (Figure 2). A similar result was obtained
with tumor specimens when MYCN expression was
compared to the expression levels of HAND2,
NTRK1, and GAP43 (Table1 and Figure 2); the
mRNA levels of STMN2 and CHGA were not
measured. We conclude that MYCN expression did
not correlate, positively or negatively, to the stage of
differentiation in neuroblastoma. As a comparison,
PCR data demonstrating a statistically significant
negative correlation between MYC and MYCN
expression were included (Table 1, and as pre-
viously reported43,44).
Overexpression of Exogenous MYCN in SK-N-SH
Neuroblastoma Cells
We next wanted to test whether overexpression of
MYCN could affect induced differentiation of cul-
tured neuroblastoma cells lacking MYCN amplifica-
tion. In order to test this, we had to work in a non-
MYCN-amplified cell system with the potential to
differentiate neuronally, which excludes most, if not
all, neuroblastoma cell lines currently available. We
chose to work with SKMYC2 cells, which are SK-N-
SH cells stably transfected with MYCN, for two
major reasons: (i) the parental cells have the
capacity to differentiate in response to a number of
different treatment protocols, and (ii) the differen-
tiated phenotypes are well characterized. To our
knowledge, there is no other non-MYCN-amplified
neuroblastoma cell line that meets these criteria.
Furthermore, these transfected cells can be grown
and selected in such a way that a majority of the
cells retain their neuroblastic features, although the
cultures always contain a small fraction of surface
adherent, S-type-like cells.27,45 In Figure 3, the
MYCN expression in SKMYC2 and in neuroblastoma
Figure 1 MYCN and TH expression in abdominal cross-sections
of an 8.5-week human fetus. ((a), (b)). MYCN expression was
detected by in situ hybridization. A bright-field image is shown in
panel (a) and a dark-field image in panel (b). (c). Immunohisto-
chemical analysis of an adjacent section with anti-TH antibodies.
The sections were counterstained with hematoxylin. Arrows
indicate a TH and MYCN-positive sympathetic chain ganglion,
and arrowheads in panel (c) indicate TH-positive sympathetic
cells migrating into the developing adrenal gland. Abbreviations:
Ao, aorta; AG, adrenal gland; DRG, dorsal root ganglion; SC,
spinal cord; SG, sympathetic ganglion; VB, vertebral body.
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cells with an amplified MYCN gene was compared.
At the mRNA level, SKMYC2 cells displayed an
MYCN expression lower than most MYCN-amplified
neuroblastoma cell lines except for the LA-N-2 cells
(Figure 3a), while the MYCN protein content in the
transfected cells was in parity with most of the
tested cell lines (Figure 3b). In nontransfected SK-N-
SH cells and the derived subclones SH-EP and SH-
SY5Y, MYCN mRNA or protein was barely detect-
able. The MYC expression is downregulated in
neuroblastoma cells with amplified MYCN 43 and
as expected, the overexpression of MYCN in SK-N-
SH cells led to a decrease in MYC (Figure 3a).
Furthermore, SKMYC2 cells downregulate the
MYCN responsive gene INHBA (angiogenesis inhi-
bitor activin A) (Figure 3c and Breit et al 46),
demonstrating that the protein resulting from the
introduced MYCN gene in the SKMYC2 cells used in
Figure 2 mRNA expression of MYCN and a set of marker genes for neuronal differentiation in neuroblastoma cell lines and tumors. In all,
27 neuroblastoma cell lines and 28 tumor specimens were analyzed using quantitative real-time RT-PCR for the expression of MYCN,
HAND2, NTRK1, GAP43, STMN2, and CHGA. Of the 27 cell lines analyzed, 20 were amplified (samples 8–27), as were seven of the 28
analyzed tumors (samples 21, 23–28). Cell lines analyzed were (in order of increasing MYCN expression) SK-N-AS (1), SK-N-SH (2),
LA-N-6 (3), SJNB-1 (4), CLB-GA (5), SK-N-FI (6), NBL-S (7), STA-NB-8 (8), NLF (9), SK-N-BE (10), STA-NB-10 (11), CHP 901 (12), STA-
NB-3 (13), LA-N-5 (14), SJNB-6 (15), TR-14 (16), NMB (17), CHP 134 (18), IMR-32 (19), UHG-NP (20), SJNB-10 (21), LA-N-1 (22), N206
(23), SMS-KCNR (24), SJNB-8 (25), SMS-KAN (26), NGP (27).
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this study was functional (Figure 3a and c). The
functionality of the transfected MYCN construct has
further been demonstrated in previous studies
showing altered b1 integrin subunit and NCAM
levels, indicating that the normal integrin-depen-
dent growth regulation had been short-circuited, a
phenomenon not observed in mock-transfected
cells.27,47,48
The SKMYC2 parental cell line, SK-N-SH, con-
tains three morphologically distinct and intercon-
vertible cell types, the N-type with neuroblastic
properties (represented by the SH-SY5Y subclone),
the surface-adherent S-type (represented by the SH-
EP subclone), and intermediate forms, I-type cells.49
In SK-N-SH cultures, N-type cells dominate and
have the capacity to differentiate neuronally.50 S-
type cells virtually lack neuronal properties and the
capacity to differentiate neuronally. In general,
SKMYC2 cell cultures contained a smaller propor-
tion of N-type cells than did cultures of untrans-
fected SK-N-SH cells (data not shown), but the
proportion of N-type cells increased as the SKMYC2
cultures grew denser (compare Figure 4a and c). To
be able to correlate morphology and MYCN expres-
sion at a cellular level in MYCN-transfected and
nontransfected cell clones, an immunofluorescence
assay for MYCN in cultured cells was developed. All
morphological subpopulations of SKMYC2 cells
displayed a nuclear MYCN staining pattern (Figure
4a–d), in contrast to the weaker, probably non-
specific, uniform fluorescence detected in the non-
MYCN-transfected SK-N-SH and SH-EP cells (Figure
4e–h).
RA- and TPA-induced Differentiation of SKMYC2
Cells
To investigate if MYCN overexpression affects
induced neuronal differentiation of neuroblastoma
cells, SKMYC2, SK-N-SH, SH-SY5Y, and SH-EP
cells were treated with 1 mM RA or 16 nM TPA,
treatments previously shown to differentiate SH-
SY5Y and SK-N-SH cells.50,51.Addition of either TPA
or RA (Figure 5a-f) to SKMYC2 cultures led to
morphological differentiation of MYCN expressing
N-type cells, seen as an extension of neurites with
growth cones and varicosities, while S-type cells
appeared unaffected. In line with these and previous
Table 1 Correlation between MYCN mRNA levels and differentiation marker genes
Cell lines (27) Tumors (28)
MYCN vs Spearman p Spearman p
MYC 0.701a 4.67E-5a 0.254a 0.192a
HAND2 0.109 0.590 0.180 0.359
NTRK1 0.165 0.411 0.153 0.438
GAP43 0.134 0.506 0.347 0.076
STMN2 0.140 0.487 n.t. n.t.
CHGA 0.200 0.317 n.t. n.t.
Spearman’s rank correlation coefficients between MYCN and MYC, HAND2, NTRK1, GAP43 STMN2, and CHGA mRNA levels in 27
neuroblastoma cell lines and 28 primary tumors (significance level is indicated; n.t.: not tested).
a
Data taken from Vandesompele et al.44
Figure 3 Expression of MYCN and MYC in neuroblastoma cell
lines ((a), (b)) and downregulation of INHBA in SKMYC2 cells (c).
(a) Northern blot analysis of the expression of MYCN and MYC in
indicated cell lines. Total RNA (15mg) was analyzed with GAPD
mRNA levels (1.5 kb) as a loading control. The endogenous
(2.7 kb) and exogenous (2.2 kb) MYCN transcripts are indicated by
arrowheads. (b) Western blot analysis of MYCN protein levels in
indicated cell lines, using actin protein levels as a loading
control. A measure of 30mg of whole cell protein lysate was
loaded in each lane. The SKMYC2 cells analyzed in (a) and (b)
were selected in 200mg/ml of Hygromycin B. (c) Quantitative real-
time RT-PCR analysis of INHBA expression in SK-N-SH and
SKMYC2 cells. The relative expression levels are presented as
mean expression7s.d. of two independent cultures, with the
expression in SKMYC2 cells set to one.
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results, virtually no cells in the SH-EP cultures
responded to either RA or TPA (not shown), while
morphologically differentiated cells in RA- and
TPA-treated SK-N-SH cultures were abundant
(Figure 5m–r).
SKMYC2 cells treated with RA and TPA were
analyzed for the expression of the neuronal marker
genes NPY and GAP43, using SH-SY5Y and SH-EP
cells as references. TPA treatment led to an
increased expression of NPY in SH-SY5Y as well
as in SKMYC2 cells. Treatment with RA resulted in
a downregulation of NPY expression in both cell
systems (Figure 6a), consistent with the develop-
ment of a cholinergic phenotype, as demonstrated
previously.52,53 The SH-SY5Y response was more
pronounced and mimicked that of the SK-N-SH cells
(Figure 6a and b). SH-EP did not express NPY
regardless of treatment. Treatment with RA resulted
in a slight upregulation of the GAP43 expression in
SH-SY5Y, SKMYC2, and SK-N-SH cells, while TPA
clearly upregulated GAP43 in these cells (Figure 6a
and b), as previously reported in SH-SY5Y cells.53,54
The NPY expression in the TPA-treated SKMYC2
cells was low compared to the expression in the
correspondingly treated SK-N-SH and SH-SY5Y
cells (Figure 6a and b). This difference could be
explained by the comparatively high proportion of
S-type cells, expressing low amounts of NPY,
present in the SKMYC2 cultures. To estimate the
Figure 4 Morphology and MYCN expression in neuroblastoma
cell lines. SKMYC2 cells grown in serum-containing medium and
analyzed at a low cell density, day 1 ((a), (b)), and at a higher cell
density at day 6 ((c), (d)). Cell morphology was assessed using
phase-contrast microscopy ((a), (c)) and nuclear MYCN expres-
sion was detected by immunofluorescence ((b), (d). SH-EP ((e), (f))
and SK-N-SH ((g), (h)) cells grown for 3 days in serum-containing
medium and analyzed by phase-contrast microscopy ((e), (g)) and
for MYCN expression by immunofluorescence ((f), (h)).
Figure 5 Morphological differentiation and MYCN expression in
SKMYC2 ((a)–(l)) and SK-N-SH ((m)–(x)) cells treated with
various differentiation-inducing agents. ((a)–(d)). SKMYC2 cells
grown in serum-containing medium for 3 days with no additives
((a), (b)), or in the presence of 16 nM TPA ((c), (d)). ((e)-(j)).
SKMYC2 cells grown in serum-containing medium for 6 days in
the presence of 1 mM RA ((e), (f)), 1 mM RAþ 100 ng/ml BDNF ((g),
(h)), or 3 nM bFGF and 5 nM IGF-I ((i), (j)). ((k)–(l)). SKMYC2 cells
grown in serum-containing medium for 4 days in the presence of
0.3mM aphidicolin and 100 ng/ml NGF. ((m)-(x)). SK-N-SH cells
grown for the same amount of time and with the same additives as
the SKMYC2 analyzed in ((a)–(l)). Cell morphology was assessed
using phase-contrast microscopy ((a), (c), (e), (g), (i), (k), (m), (o),
(q), (s), (u), (w)) and nuclear MYCN expression detected by
immunofluorescence ((b), (d), (f), (h), (j), (l), (n), (p), (r), (t), (v),
(x)). Note the diffuse, uniform fluorescent staining in the SK-N-
SH cells, contrasted to the distinct nuclear MYCN staining in the
SKMYC2 cells.
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mRNA contribution from S-type cells, HES1 expres-
sion was analyzed as HES1 mRNA is abundant in
SH-EP cells, but no or little mRNA can be detected
in SH-SY5Y cells (Figure 6a and Grynfeld et al 33).
As shown in Figure 6a, the SKMYC2 cells had
higher HES1 mRNA levels than the SH-SY5Y cells,
confirming a substantial contribution of S-type cell
mRNA in these assays.
Growth Factor-induced Differentiation of SKMYC2
Cells
To extend the analysis of the capacity of the
SKMYC2 cells to differentiate, we utilized addi-
tional protocols known to induce differentiation of
SH-SY5Y cells, including protocols employing
growth factors of importance in normal sympathetic
development.55–57 SKMYC2 and SK-N-SH cells were
treated with 1mM RA or a combination of 1 mM RA
and 100 ng/ml BDNF, which induced neurite out-
growth of neuroblastic but not S-type cells in both
SK-N-SH and SKMYC2 cultures (Figure 5g, h, s and t).
Notably, the differentiated SKMYC2 cells retained a
nuclear MYCN staining, suggesting that they differ-
entiated despite a high MYCN expression (Figure
5h). Following another published differentiation
protocol, the cells were treated with 3 nM bFGF
and 5 nM IGF-I.56 Both SKMYC2 and SK-N-SH cells
differentiated morphologically in response to these
growth factors, and nuclear staining of MYCN was
again seen in SKMYC2 cells with long neurites
(Figure 5i,j,u and v). Finally, the cells were differ-
entiated with NGF (100 ng/ml) in combination with
aphidicolin (0.3 mM), a cell cycle blocking agent,
which induces NTRK1 expression and NGF respon-
siveness in SH-SY5Y cells.57–59 As aphidicolin
blocks cell division, the number of cells in these
cultures was comparatively low and N-type neuro-
blastoma cells were few. However, the cells present
extended long neurites in the presence of NGF
(Figure 5k,l,w and x), and the differentiated
SKMYC2 cells retained a nuclear MYCN staining
pattern (Figure 5l). Interestingly, the aphidicolin/
NGF-treated SKMYC2 cells had considerably longer
neurites than SK-N-SH cells treated in the same way
(data not shown).
Differentiating SKMYC2 Cells Retain a High MYCN
Expression
Neuroblastoma cells endogenously overexpressing
MYCN as a result of gene amplification downregulate
Figure 6 Neuronal marker gene expression in RA- and TPA-
treated SKMYC2, SH-SY5Y, SK-N-SH, and SH-EP cells. (a)
Northern blot analysis of the expression of the differentiation
marker genes NPY (0.8 kb mRNA) and GAP43 (1.4 kb mRNA),
epithelial marker gene HES1 (1.7 kb mRNA), and MYCN (2.2 kb
mRNA) in SH-SY5Y, SKMYC2, and SH-EP cells. Cells were grown
for 1 day or 3 days in serum-containing medium with the addition
of 1 mM RA and 16 nM TPA, where indicated. Total RNA (15mg)
from all samples was analyzed on one gel for expression of the
genes above with GAPD mRNA levels (1.5 kb mRNA) as a loading
control. (b) Northern blot analysis of the expression of the
differentiation marker genes NPY and GAP43 in SK-N-SH and
SH-SY5Y cells, grown for 1 day or 3 days in serum-containing
medium. The exogenous (2.2 kb) MYCN transcript is indicated by
the arrowhead. Total RNA (15mg) from all samples was analyzed
on one gel with GAPD mRNA levels as a loading control.
Figure 7 Expression of MYCN in differentiating neuroblastoma
cells, as determined by Western blot analysis, using actin protein
levels as a loading control. (a) MYCN protein levels in 30mg of
whole cell lysate from SK-N-BE (2) and SKMYC2 cells cultured
for 3 or 6 days in serum-containing medium in the presence of 1
or 10mM RA as indicated. (b) MYCN protein levels in 60mg of
whole cell lysate from SK-N-SH, SKMYC2, and SH-EP cells
cultured in serum-containing medium for 3 days in the presence
of 1 mM RA or 16 nM TPA, where indicated. Molecular weight
marker positions are indicated in the right-hand margin.
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MYCN during induced differentiation.55–57 To exclude
the possibility that the effect of exogenous MYCN
was lost due to downregulation of MYCN in
differentiating SKMYC2 cells, MYCN expression
levels were analyzed in more detail. The MYCN-
amplified SK-N-BE (2) cells, which differentiate
with RA, served as a positive control. In cells treated
for 3 and 6 days, MYCN protein levels decreased
slightly, as expected (Figure 7a), while the expres-
sion in SKMYC2 cells was virtually unaffected
when treated with 1 or 10 mM RA. Furthermore,
SK-N-SH, SKMYC2, and SH-EP cells treated with
TPA or RA for 3 days were analyzed for MYCN
protein content. Neither of the treatments substan-
tially changed the MYCN protein levels (Figure 7a
and b), in agreement with mRNA expression and
immunofluorescence data in Figures 5 and 6.
Discussion
The important role of MYCN in early embryonal
development is illustrated by profound disturbances
and early embryonic death of homozygous MYCN
knockout mice. However, the role of MYCN in
cellular differentiation in relation to neuroblastoma
development has not yet been fully addressed.
Detailed MYCN expression studies performed in
mice show that MYCN is preferentially expressed at
sites with ongoing cell differentiation, tissue ma-
turation, and organogenesis.13–15 In agreement with
these results, we recently observed that in human
neuroblastoma cells the loss of a differentiated
phenotype induced by hypoxia was paralleled by
MYCN downregulation in all studied MYCN-ampli-
fied cell lines.60 We have found that MYCN is
expressed in human sympathetic neuroblasts at a
comparatively late developmental stage (week 8.5).
Clearly, neuroblasts are at this stage committed to
sympathetic neuronal development and express
several sympathetic marker genes such as TH,
HAND2, GAP43, NPY, BCL2, and STMN2.38–40 Un-
like most neuroblastoma cells, these neuroblasts
have passed the stage of ASCL1 (HASH-1) expres-
sion.40 ASCL1 is involved in the determination of
the sympathetic ganglionic lineage,61 suggesting that
normal sympathetic neuronal differentiation beyond
the stage at which most neuroblastoma cells appear
to be arrested proceeds in the presence of a
significant MYCN expression.
To further investigate the putative role of MYCN
in controlling cellular differentiation, we analyzed
the phenotypic response of non-MYCN-amplified
neuroblastoma cells with constitutive exogenous
overexpression of MYCN to several established
differentiation protocols. Under all conditions,
these cells were shown to retain their capacity to
differentiate morphologically. In none of these
settings, the differentiation was accompanied by
any substantial reduction of MYCN mRNA or
protein levels, clearly indicating that differentiation
could proceed in the presence of high MYCN
expression. We further studied the expression levels
of well-established sympathetic nervous system
neuronal/neuroendocrine differentiation markers
in neuroblastoma cell lines and tumors. Our results
clearly demonstrate an absence of correlation be-
tween the expression levels of differentiation mar-
kers and MYCN, suggesting the results from the
SKMYC2 system to be relevant also in vivo.
These findings appear to contradict in vitro data
demonstrating that overexpression of MYCN in
human neuroblastoma cells and rat cells derived
from the brain blocks induced differentiation.18,19,62
A role for the maintenance of the immature
phenotype is also suggested by the high incidence
of MYCN amplification and overexpression in a
subset of high stage, less-differentiated neuroblasto-
mas. Overexpression of MYCN in non-MYCN-
amplified neuroblastoma cells and the impact on
differentiation have not been studied in a neuronal
context, as previous MYCN overexpression studies
in non-MYCN-amplified neuroblastoma cells have
mainly utilized SH-EP cells.10,11,19 These cells
virtually lack neuroblastic properties (Ross et al,49
Rettig et al 63 and this report) and cannot be induced
to differentiate neuronally by existing differentia-
tion protocols (this report and unpublished observa-
tions). Thus, this cell system would not be expected
to be informative when studying putative effects of
MYCN on differentiation into a neuronal sympa-
thetic neuroblastoma phenotype. Nor does the
recently published study in which MYCN over-
expression in rat postmitotic sympathetic neurons
elicited the capacity of these cells to re-enter cell
cycle (but not enhanced survival) necessarily ex-
clude a specific role for MYCN during differentia-
tion.9 It is possible that the differences in outcome
between the present study and the studies using
MYCN-amplified cell lines18,19 result from differ-
ences in the total MYCN expression levels and that
extreme levels of MYCN expression will antagonize
a neuronal sympathetic phenotype, thus assuming a
functional threshold for this effect of MYCN.6 This
would be in line with a recent report showing that
overexpression of MYCN can block terminal differ-
entiation of sensory neurons.64 However, the MYCN
protein content in the SKMYC2 cells is in parity
with that of some neuroblastoma cell lines with
amplified MYCN and, more importantly, no signs of
a correlation between MYCN expression and ex-
pression of differentiation marker genes in neuro-
blastoma tumors and cell lines could be detected.
This was true even when only those tumors with the
highest MYCN expression were considered. In vivo,
not only the absolute level of expression, but also
the regulation of expression, for example, in re-
sponse to stress has to be considered. In this respect,
the behavior of SKMYC2 cells might be expected to
be closer to that of MYCN-amplified cells than that
of high MYCN expressing cells without MYCN
amplification.
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If the link between MYCN amplification and poor
prognosis cannot be explained by blocked differ-
entiation, what are the alternative explanations? It
has been shown that MYCN can functionally replace
MYC in murine development65 and we can assume
that MYCN, like MYC, is involved in a variety of
pathways that, when disturbed, can contribute to
cancer development. Presumably, the pathways
affected vary depending on the differentiation status
and the presence of additional genetic changes.
Furthermore, MYCN amplification is a result of
genetic instability, which in itself is associated with
poor prognosis and tumor progression. The picture
is further obscured by the fact that the varying
MYCN expression seen in low-stage neuroblastomas
might instead reflect the differentiation and prolif-
eration status of the tumor cells. In view of this
limited understanding of the molecular basis of
MYCN gene regulation and the possibility that
MYCN forms an integral part of a subtle transcrip-
tional network, dependent on cell type and differ-
entiation status, we can only speculate on the exact
nature of the role of MYCN in neuroblast differentia-
tion. Thus, further experiments using different
overexpressing systems in parallel with identifica-
tion of bona fide MYCN target genes are needed.
However, the data presented here strongly suggest
that expression of MYCN is compatible with normal
sympathetic neuronal development and that neuro-
nal differentiation of neuroblastoma cells is not
blocked by high MYCN levels.
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